Intellia Therapeutics, Inc.·4

Jan 10, 4:15 PM ET

Sepp-Lorenzino Laura 4

4 · Intellia Therapeutics, Inc. · Filed Jan 10, 2024

Insider Transaction Report

Form 4
Period: 2024-01-08
Sepp-Lorenzino Laura
EVP, Chief Scientific Officer
Transactions
  • Sale

    Common Stock

    2024-01-08$29.38/sh667$19,59643,927 total
  • Sale

    Common Stock

    2024-01-08$28.66/sh1,608$46,08544,594 total
Footnotes (3)
  • [F1]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.16 to $29.06, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 8, 2024 at each separate price.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.19 to $29.63, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 8, 2024 at each separate price.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4